Dominika's one-day-old daughter Emilia is part of the screening programme The entire genetic code of up to 100,000 newborn babies in England will be analysed by the NHS, with the aim of speeding ...

Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Read the ...

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period ...

Researchers suggest their work represents a breakthrough in low-cost, noninvasive cancer screening through breath analysis.

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...

The catalogue of genetic factors that have been implicated in kidney disease continues to grow. In this guide to gene–disease relationships, the authors discuss the crucial process whereby ...

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...